Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2005
06/09/2005WO2005051406A1 Ceramidase inhibitor
06/09/2005WO2005051405A1 Il-8 production promoters and use thereof
06/09/2005WO2004105737A3 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
06/09/2005WO2004012671A3 Substituted furo [2,3-b] pyridine derivatives
06/09/2005WO2003088897A3 Fab i inhibitors
06/09/2005US20050124796 Mouse cytokine receptor
06/09/2005US20050124696 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
06/09/2005US20050124693 Biguanide derivative and therapeutic agent for diabetes containing the same
06/09/2005US20050124689 Tocopherol enriched compositions and amelioration of inflammatory symptoms
06/09/2005US20050124685 Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning
06/09/2005US20050124682 Such as N-{2-[5-(methylthio)-1H-indol-3-yl]ethyl}acetamide for treatment of disorders of the melatoninergic system; hormone replacement therapy
06/09/2005US20050124680 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
06/09/2005US20050124672 Antineoplastic agents, analgesics, antipyretics; prostaglandin E2 receptor antagonists; 3-Methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, a C1-4 alkyl ester, or a non-toxic salt
06/09/2005US20050124671 Benzylcycloalkyl amines as modulators of chemokine receptor activity
06/09/2005US20050124665 Cyclopenteneones for antiischemic agents, antiinflammatory agents and aging resistance
06/09/2005US20050124658 Decahydronaphtho[2,3-c]furan derivatives
06/09/2005US20050124656 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps)
06/09/2005US20050124649 Deazapurines and uses thereof
06/09/2005US20050124647 For example, 4-hydroxy-1,1-di-(5',6'-methylendioxy-indol-2-yl)-butane; antitumor agents, particularly for treating mammary carcinoma and colon carcinoma
06/09/2005US20050124643 Steroid 3-O-sulphamate derivatives as inhibitors of oestrone sulphatase
06/09/2005US20050124642 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds
06/09/2005US20050124641 Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
06/09/2005US20050124631 For example, 2-amino-7-chloro-6-hydroxy-4-methylbenzothiazole; compounds that prevent the formation of polyglutamine containing protein aggregates; treatment of spinal and bulbar muscular atrophy, dentatorubal pallidoluysian atrophy, spinocerebellar ataxia, Alzheimers disease
06/09/2005US20050124628 Quinoline and aza indole compounds having pharmacological activity, for example, 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; use in the treatment of CNS and other disorders
06/09/2005US20050124627 Use as excitatory amino acid antagonists for combating neurodegenerative and cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's, Parkinson's or Huntington's disease, or psychoses; for example, 3-[4-(3,4-methylenedioxybenzyl)piperidino]-N-(2-oxo-2,3-dihydrobenzoxazol-6-yl)propionamide
06/09/2005US20050124624 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases
06/09/2005US20050124621 Novel inhibitors of kinases
06/09/2005US20050124617 Agonists to a cannabinoid type 2 receptor; antiinflammatory agents; immunosuppressants; nephritis
06/09/2005US20050124606 Novel benzothiazine and benzothiadiazine derivatives method for preparing same and pharmaceutical compositions containing same
06/09/2005US20050124605 E.g., substituted 2,3,5,10b-tetraaza-benzo[e]azulen-6-yl)-acetic acids, 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl)-(4,6-dimethoxy-pyrimidin-2-yloxy)-acetic acids and 2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-ylmethyl}-benzoates; treating circulatory, inflammatory, and proliferative disorders
06/09/2005US20050124603 Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
06/09/2005US20050124586 Alpha-substituted arylalkyl phosphonate derivatives
06/09/2005US20050124577 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
06/09/2005US20050124574 Purine derivatives
06/09/2005US20050124557 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia
06/09/2005US20050124555 Azulene derivatives and salts thereof
06/09/2005US20050124549 Method of modulating the proliferation of medullary thyroid carcinoma cells
06/09/2005US20050124547 Tau-conotoxin peptides
06/09/2005US20050124543 Heterologous polypeptide of the TNF family
06/09/2005US20050124050 Osteoclast differentiation inhibitors
06/09/2005US20050124004 Histamine receptor h3 polynucleotides
06/09/2005US20050124003 Using immunoaffinity selection to isolate and propagate pluripotent stem cell populations from fetal developmental tissues; cell replacement therapies
06/09/2005US20050123983 Methods and compositions for overcoming resistance to biologic and chemotherapy
06/09/2005US20050123912 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders
06/09/2005US20050123909 Compositions and methods for treating cells having double minute dna
06/09/2005US20050123899 Viricidal agent comprising mannose binding protein for use in directed destruction of viral particles associated with human immunodeficiency syndrome
06/09/2005US20050123636 Total coumarins include six active compounds, which have been identified as osthal, xanthotoxol xanthotoxin, isopimpinellin, bergapten, imperatorine; little side-effect
06/09/2005US20050123633 Obtained by fermenting soybean germ, which is used as raw material, with koji mold, thus breaking down proteins, then hydrolyzing, extracting and concentrating using solvent to produce an isoflavone aglycone concentrate
06/09/2005US20050123610 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof
06/09/2005US20050123558 Modifeid polypeptide
06/09/2005US20050123541 Anti-TNF antibodies, compositions, methods and uses
06/09/2005US20050123533 Prodrugs activated by targeted catalytic proteins
06/09/2005US20050123523 Immunostimulatory nucleic acid molecules
06/09/2005US20050123512 Binding agents, vectors, host cells; gene therapy; nucleotide sequence with DNA insert encoding polypeptide; genetic engineering; medical diagnosis
06/09/2005US20050123508 human granulocyte colony stimulating factor polypeptides having amino acid replacements in the sequence, used for treating hematopoietic, neurological or reproductive disorders
06/09/2005CA2547467A1 Piperidine compound and method for producing same
06/09/2005CA2547430A1 Receptor function regulating agent
06/09/2005CA2547326A1 Novel muscle growth regulator
06/09/2005CA2547235A1 T-type calcium channel blocker
06/08/2005EP1538207A1 Human antihuman mcp-1 antibody and antibody fragment thereof
06/08/2005EP1538202A2 Production of human alpha-galactosidase A
06/08/2005EP1538162A2 Compositions for altering mucus secretion
06/08/2005EP1538160A1 Substituted Isoquinolin-3-carboxyamides, their preparation and medical use
06/08/2005EP1538158A1 Proline ester and preparation containing the same for percutaneous administration
06/08/2005EP1537879A1 Preventive and/or therapeutic drugs for asthma
06/08/2005EP1537875A1 Preventive/remedy for arteriosclerosis
06/08/2005EP1537870A2 Methods and compositions for treating cancer
06/08/2005EP1537237A2 Use of pp2a phosphatase modulators in the treatment of mental disorders
06/08/2005EP1537129A1 Akt inhibitors, pharmaceutical compositions, and uses thereof
06/08/2005EP1537124A1 C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants
06/08/2005EP1537112A1 Condensed pyridines and pyrimidines with tie2 (tek) activity
06/08/2005EP1537110A2 Triazospiro compounds having nociceptin receptor affinity
06/08/2005EP1537106A1 Dihydropyrazolopyridine compounds
06/08/2005EP1537104A1 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist
06/08/2005EP1537086A2 Novel phenanthridines
06/08/2005EP1537084A1 Substituted 2-alkylamine nicotinic amide derivatives and use there of
06/08/2005EP1537076A1 Novel vinyl carboxylic acid derivatives and their therapeutical use
06/08/2005EP1537075A2 Diarylurea derivatives and their use as chloride channel blockers
06/08/2005EP1537074A1 Cathepsin cysteine protease inhibitors
06/08/2005EP1537073A2 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands
06/08/2005EP1537072A1 Substituted aminoethers for the treatment of alzheimer s disease
06/08/2005EP1537068A1 Materials and methods for treating hypercholesterolemia
06/08/2005EP1536863A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
06/08/2005EP1536839A2 Method for treating diseases with omega interferon
06/08/2005EP1536835A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
06/08/2005EP1536834A2 Design of chemokine analogs for the treatment of human diseases
06/08/2005EP1536824A2 Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
06/08/2005EP1536813A2 Compositions and methods comprising protein activated receptor antagonists
06/08/2005EP1536804A2 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
06/08/2005EP1536801A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/08/2005EP1536800A1 Synergistic interaction of abacavir and alovudine
06/08/2005EP1536792A1 Pramipexole once-daily dosage form
06/08/2005EP1536777A1 Use of nf-kappa b inhibitors for the treatment of mastitis
06/08/2005EP1536775A1 Compositions comprising hmg-coa reductase inhibitor
06/08/2005EP1465854A4 Chalcone derivatives and their use to treat diseases
06/08/2005EP1458706A4 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
06/08/2005EP1373269B1 Jun kinase inhibitors
06/08/2005EP1373231B1 3-heterocyclyl-propano-hydroxamic acid as pcp inhibitors
06/08/2005EP1370528B1 Mch antagonists and their use in the treatment of obesity
06/08/2005EP1337526B1 Substituted imidazoles useful in the treatment of inflammatory diseases
1 ... 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 ... 1564